This announcement is a separate document:
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- Welcome RewardsOpen an account and get up to HKD1800!
- Enjoy limited-time 5%+5% returns on Cash PlusInvest any amount and enjoy a 5% average return on Cash Plus + 5% welcome reward
- Join Futubull Membership ProgramUnlock 11 Premier Benefits
- Referral PromotionBring a friend and collect up to HK$600 in rewards
- Learn PremiumAnalyst 1V1 online teaching
- Stock TransferSwitch to Futu and get up to HK$7,000 in rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
SC 13G: Statement of acquisition of beneficial ownership by individuals
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
18:53
Affected by the results of Novo-Nordisk A/S's weight loss drug trial, the Europe Stoxx Medical Care Index fell by 4.4%, marking the largest single-day drop since March 2020.
NVO-2.38%
18:52
Novo-Nordisk A/S fell over 19% in Pre-Market Trading, as the company previously announced experimental data for its new weight loss drug CagriSema.
NVO-2.38%
18:49
The stock price of Novo-Nordisk A/S fell more than 17% in Pre-Market Trading after the release of Cagrisema data.
NVO-2.38%